Enliven Therapeutics Ownership | Who Owns Enliven Therapeutics?
Enliven Therapeutics Ownership Summary
Enliven Therapeutics is owned by 21.08% institutional investors, 7.52% insiders, and 71.39% retail investors. Orbimed advisors is the largest institutional shareholder, holding 14.05% of ELVN shares.
ELVN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Enliven Therapeutics | 21.08% | 7.52% | 71.39% |
| Sector | Healthcare Stocks | 35.49% | 11.78% | 52.72% |
| Industry | Biotech Stocks | 34.84% | 11.71% | 53.45% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Orbimed advisors | 7.96M | 14.05% | $312.01M |
| Fmr | 6.83M | 12.05% | $267.71M |
| Polar capital | 5.07M | 8.94% | $198.58M |
| Blackrock funding, inc. /de | 3.68M | 6.50% | $144.44M |
| Commodore capital lp | 3.27M | 5.78% | $128.38M |
| Vestal point capital, lp | 3.25M | 5.74% | $127.40M |
| Vanguard group | 2.80M | 4.51% | $43.15M |
| Bellevue group | 2.32M | 4.10% | $90.98M |
| Fairmount funds management | 1.86M | 3.27% | $72.74M |
| Citadel advisors | 1.74M | 3.08% | $68.36M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Commodore capital lp | 3.27M | 7.43% | $128.38M |
| Orbimed advisors | 7.96M | 6.21% | $312.01M |
| Fairmount funds management | 1.86M | 5.25% | $72.74M |
| Exome asset management | 220.09K | 4.46% | $8.63M |
| Novo | 1.28M | 4.07% | $50.18M |
| Avidity partners management lp | 400.00K | 3.73% | $16.49M |
| Vestal point capital, lp | 3.25M | 3.56% | $127.40M |
| Stempoint capital lp | 363.44K | 2.77% | $14.25M |
| First turn management | 623.84K | 2.73% | $24.45M |
| Vr adviser | 1.73M | 2.53% | $67.67M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Bellevue group | 2.32M | 2.17% | 2.32M |
| Polar capital | 5.07M | 0.71% | 1.55M |
| Siren | 746.23K | 0.81% | 746.23K |
| Alliancebernstein | 771.88K | 0.00% | 735.04K |
| Baker bros. advisors lp | 905.19K | 0.20% | 633.78K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fairmount funds management | 1.86M | 5.25% | -1.86M |
| Janus henderson group | 11.00K | 0.00% | -1.66M |
| Point72 asset management | - | - | -1.50M |
| Vr adviser | 1.73M | 2.53% | -1.50M |
| Commodore capital lp | 3.27M | 7.43% | -1.42M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Bellevue group | 2.32M | 2.17% | 2.32M | $90.98M |
| Siren | 746.23K | 0.81% | 746.23K | $29.25M |
| Caption management | 370.00K | 0.08% | 370.00K | $14.50M |
| Capricorn fund managers | 369.40K | 2.26% | 369.40K | $14.48M |
| Stempoint capital lp | 363.44K | 2.77% | 363.44K | $14.25M |
Sold Out
| Holder | Change |
|---|---|
| Clearstead advisors | -5.00 |
| Td capital management | -16.00 |
| Stephens consulting | -20.00 |
| Amundi | -23.00 |
| Group one trading | -34.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 90 | -29.13% | 11,947,495 | -80.85% | 21 | 0.21% | 64 | -1.54% | 17 | -62.22% |
| Dec 31, 2025 | 85 | -36.09% | 19,456,209 | -67.24% | 31 | 0.34% | 42 | -46.84% | 34 | 13.33% |
| Sep 30, 2025 | 52 | -57.72% | 9,174,149 | -84.56% | 17 | 0.14% | 34 | -58.02% | 10 | -56.52% |
| Jun 30, 2025 | 122 | 0.83% | 59,425,065 | 19.12% | 114 | 1.14% | 80 | 23.08% | 23 | -30.30% |
| Mar 31, 2025 | 14 | -87.27% | 19,292,189 | -60.47% | 38 | 0.38% | 5 | -92.19% | 3 | -88.00% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | $9.19K |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | $137.38K |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | $52.40K |
| Apr 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | $6.41K |
| Apr 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | $114.64K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | 6 |
| 2026 Q1 | - | 21 |
| 2025 Q4 | - | 11 |
| 2025 Q3 | - | 28 |
| 2025 Q2 | - | 28 |
ELVN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools